Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.